BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 14987499)

  • 1. [EVAN-65 project: evaluation of the effectiveness of pneumococcus vaccination in the elderly population over 65].
    Vila Córcoles A; Ochoa Gondar O; Hospital Guardiola I; Bria Ferre X; Llor Vila C; Montañes Boncompte D;
    Aten Primaria; 2004 Feb; 33(3):149-53. PubMed ID: 14987499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience.
    Baldo V; Cocchio S; Gallo T; Furlan P; Romor P; Bertoncello C; Buja A; Baldovin T
    PLoS One; 2016; 11(11):e0166637. PubMed ID: 27846277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between pneumococcal vaccination and cardiovascular outcomes: a systematic review and meta-analysis of cohort studies.
    Vlachopoulos CV; Terentes-Printzios DG; Aznaouridis KA; Pietri PG; Stefanadis CI
    Eur J Prev Cardiol; 2015 Sep; 22(9):1185-99. PubMed ID: 25252595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention of community-acquired pneumonia in adults].
    Barros M M; Cartagena S C; Bavestrello F L
    Rev Chilena Infectol; 2005; 22 Suppl 1():s67-74. PubMed ID: 16163421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects.
    Vila-Córcoles A; Ochoa-Gondar O; Llor C; Hospital I; Rodríguez T; Gómez A
    Eur Respir J; 2005 Dec; 26(6):1086-91. PubMed ID: 16319340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prevention of Streptococcus pneumoniae (pneumococcal) infections in adults].
    Ludwig E; Mészner Z;
    Orv Hetil; 2014 Dec; 155(50):1996-2004. PubMed ID: 25481502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 13-valent pneumococcal conjugate vaccination of adults on lower respiratory tract infections and antibiotic use in primary care: secondary analysis of a double-blind randomized placebo-controlled study.
    van Werkhoven CH; Bolkenbaas M; Huijts SM; Verheij TJM; Bonten MJM
    Clin Microbiol Infect; 2021 Jul; 27(7):995-999. PubMed ID: 32971253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination in Patients With Heart Disease. How Long Should We Wait?
    Barrios V; Escobar C
    Rev Esp Cardiol (Engl Ed); 2019 Jun; 72(6):515. PubMed ID: 30292706
    [No Abstract]   [Full Text] [Related]  

  • 9. [Economic evaluation of pneumococcal vaccination in adults aged over 65 years in Castilla y León (SPAIN)].
    López-Gobernado M; Pérez-Rubio A; López-García E; Mayo Iscar A; Cabezas Pascual C; Eiros JM
    Rev Esp Geriatr Gerontol; 2019; 54(6):309-314. PubMed ID: 31307781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of the CAPAMIS study: effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke.
    Vila-Corcoles A; Hospital-Guardiola I; Ochoa-Gondar O; de Diego C; Salsench E; Raga X; Fuentes-Bellido CM
    BMC Public Health; 2010 Jan; 10():25. PubMed ID: 20085658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA): what is the future of pneumococcal conjugate vaccination in elderly?
    van Werkhoven CH; Bonten MJ
    Future Microbiol; 2015; 10(9):1405-13. PubMed ID: 26347153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease.
    Walters JA; Tang JN; Poole P; Wood-Baker R
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD001390. PubMed ID: 28116747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
    Vila-Córcoles A; Ochoa-Gondar O; Hospital I; Ansa X; Vilanova A; Rodríguez T; Llor C;
    Clin Infect Dis; 2006 Oct; 43(7):860-8. PubMed ID: 16941367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly: Exploratory analysis of the CAPiTA trial.
    Huijts SM; Coenjaerts FEJ; Bolkenbaas M; van Werkhoven CH; Grobbee DE; Bonten MJM;
    Clin Microbiol Infect; 2018 Jul; 24(7):764-770. PubMed ID: 29050992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumococcal polysaccharide vaccine may not prevent hospitalization for pneumonia in elderly individuals.
    Skull SA; Andrews RM; Byrnes GB; Kelly HA; Nolan TM; Brown GV; Campbell DA
    Clin Infect Dis; 2007 Feb; 44(4):617; author reply 617-8. PubMed ID: 17260423
    [No Abstract]   [Full Text] [Related]  

  • 16. Herd effects of child vaccination with pneumococcal conjugate vaccine against pneumococcal non-invasive community-acquired pneumonia: What is the evidence?
    van Werkhoven CH
    Hum Vaccin Immunother; 2017 May; 13(5):1177-1181. PubMed ID: 27937061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the introduction of pneumococcal conjugate vaccination on pneumonia in The Gambia: population-based surveillance and case-control studies.
    Mackenzie GA; Hill PC; Sahito SM; Jeffries DJ; Hossain I; Bottomley C; Uchendu U; Ameh D; Ndiaye M; Osuorah CD; Adeyemi O; Pathirana J; Olatunji Y; Abatan B; Ahameefula E; Muhammad BS; Fombah AE; Saha D; Mackenzie R; Plumb I; Akano A; Ebruke B; Ideh RC; Kuti B; Githua P; Olutunde E; Ofordile O; Green E; Usuf E; Badji H; Ikumapayi UNA; Manjang A; Salaudeen R; Nsekpong ED; Jarju S; Antonio M; Sambou S; Ceesay L; Lowe-Jallow Y; Sowe D; Jasseh M; Mulholland K; Knoll M; Levine OS; Howie SR; Adegbola RA; Greenwood BM; Corrah T
    Lancet Infect Dis; 2017 Sep; 17(9):965-973. PubMed ID: 28601421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design.
    McLaughlin JM; Jiang Q; Isturiz RE; Sings HL; Swerdlow DL; Gessner BD; Carrico RM; Peyrani P; Wiemken TL; Mattingly WA; Ramirez JA; Jodar L
    Clin Infect Dis; 2018 Oct; 67(10):1498-1506. PubMed ID: 29790925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly.
    Kawakami K; Kishino H; Kanazu S; Takahashi K; Iino T; Sawata M; Musey L
    Hum Vaccin Immunother; 2018; 14(8):1931-1938. PubMed ID: 29580133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study.
    Leventer-Roberts M; Feldman BS; Brufman I; Cohen-Stavi CJ; Hoshen M; Balicer RD
    Clin Infect Dis; 2015 May; 60(10):1472-80. PubMed ID: 25669354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.